Drug Patents owned by Ucb Inc

1. Drug name - BRIVIACT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6911461 UCB INC 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
Feb, 2026

(3 years from now)

CN1740151A UCB INC 2-Oxo - -1 - Pyrrolidine Derivative, Preparation Method And Application Thereof
Sep, 2007

(15 years ago)

CN1740150A UCB INC 2-Oxo - -1 - Pyrrolidine Derivative, Preparation Method And Application Thereof
Oct, 2007

(14 years ago)

CN1303066C UCB INC 2-Oxo - -1 - Pyrrolidine Derivative, Preparation Method And Application Thereof
Jul, 2010

(12 years ago)

CN1680314A UCB INC 2-Oxo - -1 - Pyrrolidine Derivative, Preparation Method And Application Thereof
Jul, 2010

(12 years ago)

CN1404470A UCB INC 2-Oxo - -1 - Pyrrolidine Derivative, Preparation Method And Application Thereof
Apr, 2015

(7 years ago)

CN1179944C UCB INC 2-Oxo - -1 - Pyrrolidine Derivative, Preparation Method And Application Thereof
Apr, 2015

(7 years ago)

CN1404469A UCB INC 2-Oxo - -1 - Pyrrolidine Derivative, Preparation Method And Application Thereof
Feb, 2021

(1 year, 7 months ago)

CN1208319C UCB INC 2-Oxo - -1 - Pyrrolidine Derivative, Preparation Method And Application Thereof
Feb, 2021

(1 year, 7 months ago)

IN200500340P3 UCB INC Compound Of General Formula (A)
Feb, 2021

(1 year, 7 months ago)

IN200201000P3 UCB INC A 2-Oxo-1-Pyrrolidine Compound Or Pharmaceutical Salts Thereof
Feb, 2021

(1 year, 7 months ago)

IN196025B UCB INC [2-Oxo-1-Pyrrolidine Derivatives] Process For Preparing
Feb, 2021

(1 year, 7 months ago)

IN200075B UCB INC A 2- Oxo-1-Pyrrolidine Compound Or Pharmaceutical Salts
Feb, 2021

(1 year, 7 months ago)

IN234848B UCB INC Compound Of General Formula (A)
Feb, 2021

(1 year, 7 months ago)

EP1447399B9 UCB INC 2-Oxo-1-Pyrrolidine Derivative And Its Pharmaceutical Uses
Feb, 2021

(1 year, 7 months ago)

EP1447399B1 UCB INC 2-Oxo-1-Pyrrolidine Derivative And Its Pharmaceutical Uses
Feb, 2021

(1 year, 7 months ago)

EP1447399A1 UCB INC 2-Oxo-1-Pyrrolidine Derivative And Its Pharmaceutical Uses
Feb, 2021

(1 year, 7 months ago)

EP1477478A2 UCB INC 2-Oxo-1-Pyrrolidine Derivatives, Process For Preparing Them And Their Uses.
Feb, 2021

(1 year, 7 months ago)

EP1477478A3 UCB INC 2-Oxo-1-Pyrrolidine Derivatives, Process For Preparing Them And Their Uses.
Feb, 2021

(1 year, 7 months ago)

EP1265862A2 UCB INC 2-Oxo-1-Pyrrolidine Derivatives, Processes For Preparing Them And Their Uses
Feb, 2021

(1 year, 7 months ago)

EP1263727A1 UCB INC 2-Oxo-1-Pyrrolidine Derivatives, Process For Preparing Them And Their Uses
Feb, 2021

(1 year, 7 months ago)

EP1477478B1 UCB INC 2-Oxo-1-Pyrrolidine Derivatives, Process For Preparing Them And Their Uses.
Feb, 2021

(1 year, 7 months ago)

EP1265862B1 UCB INC 2-Oxo-1-Pyrrolidine Derivatives, Processes For Preparing Them And Their Uses
Feb, 2021

(1 year, 7 months ago)

EP1263727B1 UCB INC 2-Oxo-1-Pyrrolidine Derivatives, Process For Preparing Them And Their Uses
Feb, 2021

(1 year, 7 months ago)

EP1452524B1 UCB INC 2-Oxo-1-Pyrrolidine Derivative And Its Pharmaceutical Uses
Feb, 2021

(1 year, 7 months ago)

EP1452524A1 UCB INC 2-Oxo-1-Pyrrolidine Derivative And Its Pharmaceutical Uses
Feb, 2021

(1 year, 7 months ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10729653 UCB INC Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives Apr, 2030

(7 years from now)

Drugs and Companies using BRIVARACETAM ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
50MG/5ML (10MG/ML) SOLUTION;INTRAVENOUS Prescription

2. Drug name - KEPPRA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8802142 UCB INC Pharmaceutical compositions comprising levetiracetam and process for their preparation Jun, 2031

(8 years from now)

US8802142

(Pediatric)

UCB INC Pharmaceutical compositions comprising levetiracetam and process for their preparation Dec, 2031

(9 years from now)

More Information on Dosage
Strength Dosage Availability
1GM TABLET;ORAL Prescription
250MG TABLET;ORAL Prescription
500MG TABLET;ORAL Prescription
750MG TABLET;ORAL Prescription

3. Drug name - KEPPRA XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7858122 UCB INC Extended release formulation of levetiracetam Sep, 2028

(5 years from now)

Drugs and Companies using LEVETIRACETAM ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
500MG TABLET, EXTENDED RELEASE;ORAL Prescription
750MG TABLET, EXTENDED RELEASE;ORAL Prescription

4. Drug name - NAYZILAM

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9687495 UCB INC Methods and systems for the delivery of a therapeutic agent Jan, 2028

(5 years from now)

US8809322 UCB INC Methods and compositions for the delivery of a therapeutic agent Jan, 2028

(5 years from now)

US8217033 UCB INC Methods and compositions for the delivery of a therapeutic agent Jan, 2028

(5 years from now)

US9289432 UCB INC Methods and compositions for the delivery of a therapeutic agent Jan, 2028

(5 years from now)

Drugs and Companies using MIDAZOLAM ingredient

Treatment: Acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patients with epilepsy 12 years of age and older

Dosage: SPRAY;NASAL

More Information on Dosage
Strength Dosage Availability
5MG/SPRAY SPRAY;NASAL Prescription

5. Drug name - NEUPRO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8617591 UCB INC Transdermal delivery system for the administration of rotigotine Jul, 2023

(9 months from now)

US8246980 UCB INC Transdermal delivery system Nov, 2025

(3 years from now)

US8246979 UCB INC Transdermal delivery system for the administration of rotigotine Sep, 2027

(4 years from now)

US10130589 UCB INC Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine Dec, 2030

(8 years from now)

US10350174 UCB INC Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine Dec, 2030

(8 years from now)

US9925150 UCB INC Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine Mar, 2032

(9 years from now)

Drugs and Companies using ROTIGOTINE ingredient

Treatment: A method for the treatment of a patient suffering from a disease treatable with rotigotine, comprising applying the claimed transdermal delivery system (tds) to the skin of the patient; Treatment of signs and symptoms of parkinson's disease by application of claimed transdermal system; treatment of restless legs syndrome by application of claimed transdermal delivery system

Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL

More Information on Dosage
Strength Dosage Availability
1MG/24HR FILM, EXTENDED RELEASE;TRANSDERMAL Prescription
2MG/24HR FILM, EXTENDED RELEASE;TRANSDERMAL Prescription
3MG/24HR FILM, EXTENDED RELEASE;TRANSDERMAL Prescription
4MG/24HR FILM, EXTENDED RELEASE;TRANSDERMAL Prescription
6MG/24HR FILM, EXTENDED RELEASE;TRANSDERMAL Prescription
8MG/24HR FILM, EXTENDED RELEASE;TRANSDERMAL Prescription

6. Drug name - VIMPAT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE38551 UCB INC Anticonvulsant enantiomeric amino acid derivatives
Mar, 2022

(6 months ago)

EP1038522A2 UCB INC Anticonvulsant Enantiomeric Amino Acid Derivatives
Mar, 2017

(5 years ago)

EP1038522B1 UCB INC Anticonvulsant Enantiomeric Amino Acid Derivatives
Mar, 2017

(5 years ago)

EP1038522A3 UCB INC Anticonvulsant Enantiomeric Amino Acid Derivatives
Mar, 2017

(5 years ago)

EP888289A1 UCB INC Anticonvulsant Enantiomeric Amino Acid Derivatives
Mar, 2022

(6 months ago)

EP888289B1 UCB INC Anticonvulsant Enantiomeric Amino Acid Derivatives
Mar, 2022

(6 months ago)

Drugs and Companies using LACOSAMIDE ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
50MG TABLET;ORAL Prescription
100MG TABLET;ORAL Prescription
150MG TABLET;ORAL Prescription
200MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.